Starton Therapeutics

Transforming therapies with proprietary dermal delivery technology, so people with cancer live better, longer

Start a new standard

Starton Therapeutics is transforming standard-of-care therapies with proprietary continuous delivery technology, so people with cancer can receive continuous treatment to live better, longer.

Targeted continuous delivery

We transform FDA-approved medicines and leverage our dermal delivery systems to establish new profiles. Our platform technology enables lower but longer drug exposure and the potential for improved efficacy.

Careers

Building a team dedicated to delivering breakthrough, transformative products for patients with blood cancers.We offer comprehensive and competitive health, financial, paid time off and many other benefits designed to promote the health and well-being of our employees and their families.

News and Events

October 29, 2024

Starton Therapeutics Announces Notice of Allowance for U.S. Patent Application 17/518,930 “Continuous Delivery of Lenalidomide and Other Immunomodulatory Agents” Including Transdermal Administration

PARAMUS, N.J., October 29, 2024 – Starton Therapeutics Inc. (“Starton” or the “Company”), a clinical-stage biotechnology company transforming standard-of-care therapies with proprietary dermal technologies, announced today that the U.S….

September 24, 2024

Starton Therapeutics’ Chief Executive Officer Chosen as 2024 Honoree by the Icla da Silva Foundation

PARAMUS, N.J., – Starton Therapeutics Inc. (“Starton” or the “Company”), a clinical-stage biotechnology company transforming standard-of-care therapies with proprietary dermal technologies, is pleased to announce that its Chairman and…